-K D Robertson Researcher Activity Profile

Research Author Detailed Information 

K D Robertson Publication Rate By Year

K D Robertson has published 2 paper(s) in 2006, 5 paper(s) in 2007, 4 paper(s) in 2008, for a total of 11 research publications in total.

K D Kd Robertson Author Information

LAST NAME: robertson

FIRST NAME: K D

INITIALS: kd

AFFILIATION:

Papers

K D Robertson's Publication Record

1. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Year Published: 2007
Department of Biochemistry & Molecular Biology, UF-Shands Cancer Center Program in Cancer Genetics, Epigenetics and Tumor Virology and Genetics Institute, College of Medicine, University of Florida, Gainesville, FL, USA.
2. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Year Published: 2006
Department of Biochemistry and Molecular Biology and University of Florida Shands Cancer Center Program in Cancer Genetics, Epigenetics, and Tumor Virology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
3. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. Year Published: 2006
Department of Anatomy and Cell Biology, Shands Cancer Center, University of Florida College of Medicine, Gainesville, FL 32611-3633, USA.
4. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. Year Published: 2007
National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-799, South Korea.
5. Histone deacetylase inhibitors for cancer therapy. Year Published: 2007
National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kimty@snu.ac.kr
6. Histone deacetylase inhibitors for cancer therapy. Year Published: 2007
National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kimty@snu.ac.kr
7. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Year Published: 2008
Department of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Box 100245, 1600 SW Archer Rd., Gainesville, FL 32610, USA.
8. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Year Published: 2008
Department of Biochemistry and Molecular Biology, University of Florida, College of Medicine, Box 100245, 1600 SW Archer Rd., Gainesville, FL 32610, USA.
9. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. Year Published: 2007
National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-799, South Korea.
10. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Year Published: 2008
11. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Year Published: 2008
Department of Biochemistry and Molecular Biology, UF Shands Cancer Center Program in Cancer Genetics, Epigenetics, and Tumor Virology, University of Florida, PO Box 100245, Gainesville, FL 32610, USA.